Analytical Method Transfer is the formal, documented process that qualifies a receiving unit (RU) to use an analytical procedure that originated in a transferring unit (TU)—demonstrating the RU has the knowledge and ability to perform the procedure as intended and to obtain reliable, comparable results. AMT is critical when moving testing between sites (including CDMOs/CROs) or into QC, and it is conducted under a pre-approved transfer protocol with predefined, appropriate acceptance criteria.
The transfer protocol
A pre-approved protocol—agreed by TU and RU—defines scope/purpose, responsibilities, materials/reagents/instruments (with required specs), the detailed procedure, samples and experiments to run, and statistically justified acceptance criteria and analyses to judge success.
Common approaches (per USP <1224> and current practice)
- Comparative testing (most common): TU and RU analyze the same predefined samples (ideally homogeneous lots). Results are compared statistically to the protocol’s acceptance criteria; for stability-indicating procedures, include forced-degradation or impurity-spiked samples at both sites.
- Co-validation (interlaboratory covalidation): RU participates in validation while the method is being validated; data contribute to assessing reproducibility across labs, qualifying the RU as part of validation.
- (Re)validation / partial revalidation at RU: Where risk indicates, the RU repeats a focused subset of validation characteristics (or full validation if warranted) to confirm performance in the new environment—consistent with the analytical lifecycle view in ICH Q2(R2)/Q14.
- Transfer waiver (risk-based, justified): In defined low-risk cases, formal testing may be waived with documentation (e.g., simple compendial procedures already verified for the RU per USP <1226>).
Keys to success
- Method robustness & lifecycle readiness: Methods developed/optimized with an ATP and risk-based robustness studies (ICH Q14) transfer more reliably; fragile methods frequently fail transfer.
- Clear, unambiguous procedures: Detailed instructions (system suitability, controls, integration rules, data handling) reduce interpretation differences at RU. (Principle reflected across USP/ICH lifecycle materials.)
- Training & knowledge transfer: Planned training and knowledge capture within the PQS (ICH Q10) support consistent execution between sites.
- Materials/controls alignment: Use common reference standards/controls and, where feasible, identical samples across TU/RU during comparative studies to isolate inter-laboratory effects (FDA notes analyzing the same samples and, for SIMs, forced-degradation at both sites).
Deliverables
- Transfer protocol (pre-approved, with predefined acceptance criteria and statistical plan).
- Executed data package (comparative/covalidation/revalidation data; raw data & calculations; SST and control chart summaries if used).
- Transfer report with conclusions against criteria and any required CAPA or lifecycle updates.
Regulatory Guidance
- USP ⟨1224⟩ Transfer of Analytical Procedures — scope, responsibilities, and transfer strategies; defines AMT as qualifying the RU to perform the TU procedure as intended. USP
- FDA (2015) Analytical Procedures & Methods Validation — describes comparative studies for transfers, including use of forced-degradation samples for stability-indicating methods. U.S. Food and Drug Administration
- ICH Q2(R2) and ICH Q14 — situate transfer within the analytical procedure lifecycle; allow risk-based (partial) revalidation appropriate to impact. European Medicines Agency (EMA)U.S. Food and Drug Administration
- USP ⟨1226⟩ Verification of Compendial Procedures — basis for verification at the RU and potential waiver scenarios for simple compendial methods. USP
- ICH Q10 Pharmaceutical Quality System — frames knowledge management and technology transfer within the PQS.